Session II: New light on CRC epidemiology

WEO CRC Screening Committee Meeting
Barcelona, 2019
Mortality due to screen-detected and interval cancer

Montse Garcia, Rebeca Sanz-Pamplona, Núria Milà, Carmen Vidal, Elvira Torné, Gemma Ibáñez-Sanz, Noémie Travier, Gemma Binefa, Víctor Moreno

Catalan Institute of Oncology-IDIBELL; Barcelona Health Consortium
Objective

The aim was to analyze the mortality in participants of a population-based fecal occult blood test screening diagnosed with colorectal cancer (CRC) comparing screen-detected and interval cancers.
Methods

Study population: Screening participants diagnosed with CRC during the screening process or the interval between invitations.

Screening Period: 2000-2015 [guaiac-based test and immunochemical test]

Follow-up: cases were censored at five years.

Methods: Hospital administration data was used to identify invasive CRC. Mortality was obtained from the National Statistics Institute, April 2019.

Analysis: Cox regression model adjusted for confounding variables.
Results

Of 396 CRC, 269 were screen-detected and 127 were diagnosed within 24-30 months (32%)

Interval rate for FIT: 20%
5-year mortality: 11.6%
## Results

<table>
<thead>
<tr>
<th></th>
<th>HRa</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screen-detected</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Interval CRC</td>
<td>1.91</td>
<td>(1.06-3.43)</td>
</tr>
<tr>
<td><strong>Age at diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Continuous)</td>
<td>1.00</td>
<td>(0.94-1.05)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.04</td>
<td>(0.57-1.91)</td>
</tr>
<tr>
<td><strong>Cancer Staging</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>III-IV</td>
<td>5.75</td>
<td>(2.76-11.98)</td>
</tr>
</tbody>
</table>

**Advanced cancers (stage III-IV)**

![Survival Probability Graph](image_url)
Discussion

Interval cancers: Rapid growing tumors or just false negative results?

False negative results: Which tumors have more propensity to bleed?

Biology differences: Are interval cancers more aggressive? Are they more lethal?

Survival curves for interval cancers and control group cancers (non-screened population) are equivalent
Conclusions

There are differences in mortality according the type of diagnosis and it is not only explained by the delay of diagnosis and consequently, cancer staging.

Further research is needed to identify which proportion of interval cancers are aggressive and fast-growing tumors.
Funding

This study was partially cofunded by the Carlos III Health Institute, the European Regional Development Fund – a way to build Europe-(PI12/00992, PI16/00588) and by the Department of Universities and Research (2017 SGR 1283) of the Government of Catalonia.